Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Wang, Zhijie
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. [electronic resource] - JAMA oncology May 2019 - 696-702 p. digital
Publication Type: Journal Article
2374-2445
10.1001/jamaoncol.2018.7098 doi
Aged
Antineoplastic Agents, Immunological--therapeutic use
B7-H1 Antigen--antagonists & inhibitors
Biomarkers, Tumor--genetics
Carcinoma, Non-Small-Cell Lung--blood
Circulating Tumor DNA
Female
High-Throughput Nucleotide Sequencing
Humans
Immunotherapy
Lung Neoplasms--blood
Male
Middle Aged
Mutation
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. [electronic resource] - JAMA oncology May 2019 - 696-702 p. digital
Publication Type: Journal Article
2374-2445
10.1001/jamaoncol.2018.7098 doi
Aged
Antineoplastic Agents, Immunological--therapeutic use
B7-H1 Antigen--antagonists & inhibitors
Biomarkers, Tumor--genetics
Carcinoma, Non-Small-Cell Lung--blood
Circulating Tumor DNA
Female
High-Throughput Nucleotide Sequencing
Humans
Immunotherapy
Lung Neoplasms--blood
Male
Middle Aged
Mutation
Programmed Cell Death 1 Receptor--antagonists & inhibitors